Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease - Wikidata - wikimedia - TriplyDB

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease

http://www.wikidata.org/entity/Q36590934

about

Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature.Fabry disease and enzyme replacement therapy in classic patients with same mutation: different formulations--different outcome?Fabry disease: dose matters.Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.

P2860

Q33645550-3C32833C-8F76-4134-8E69-7D9698BEF936 Q34304963-9485AB89-47CB-4216-A846-3FF3BA14B17C Q36624746-C83B8BDD-7C79-4EB5-A2E2-8A3DD1037622 Q37329223-606DFFF1-4627-4900-BC30-B52FCE1B55C0 Q37670334-27989968-140E-468A-A26F-8E98EF877640 Q38184922-0FC28B0F-BC6A-4AA9-8E53-76209E6D1EBA Q38949519-9E9BA3E7-B904-4770-AC24-9D3D64FCD6A6 Q41147394-42B7399D-F3B7-41AF-9476-CA78417AF93A Q42389941-CC479063-03CA-4BC0-844F-C2F018FFDC1A Q43097259-6E440220-4998-44BA-88F0-019CF0E511DA Q50043588-37E2F4BC-15ED-49BE-997A-83862C4D3B40

P2860

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease

http://www.wikidata.org/entity/Q36590934

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Effects of switching from agal ...... ts with anderson-fabry disease

@ast

Effects of switching from agal ...... ts with anderson-fabry disease

@en

type

label

Effects of switching from agal ...... ts with anderson-fabry disease

@ast

Effects of switching from agal ...... ts with anderson-fabry disease

@en

prefLabel

Effects of switching from agal ...... ts with anderson-fabry disease

@ast

Effects of switching from agal ...... ts with anderson-fabry disease

@en

P1433

Q36590934-3BCC7E5E-FF6E-4CD4-8884-DFE3759EE8A1

P1476

Q36590934-1D48078A-AFB1-4953-8B6A-B0330F78B352

P2093

Q36590934-3BA9CC46-AD45-4C18-8526-D7DAA977744F

Q36590934-6BD1EADC-363A-4A01-84C4-3E6F07852E9F

Q36590934-880FB5D3-5F93-4989-A6A8-D5F32A2F01DF

Q36590934-BF44640F-B56E-4D2F-B182-1E3E73A13D2B

Q36590934-DD5455EE-4AB9-49AA-ABEC-911C5610FD4B

Q36590934-E88C39DD-EA4B-46BF-A587-FBFB8F778462

Q36590934-EE3160CA-4DC6-45DA-9C4F-0C0ED703BC5C

Q36590934-F75F4A02-D8C8-47C3-8151-0153B2463C9C

P2860

Q36590934-0F4DF7A0-D27C-463F-B8D7-1A5D75BF422C

Q36590934-11C178BC-13B6-4F84-A639-F89FF7E25B2C

Q36590934-13E93658-FBBB-4AC6-B221-BEA8FC6F3A6C

Q36590934-1EC09EB5-01E4-452F-B9DC-6A72446DEA50

Q36590934-308C0255-3615-4A59-A0FE-67793CC4B37B

Q36590934-3B9B7417-2A8A-4426-A0CA-89A712B3C42F

Q36590934-3C7674C5-70A2-4CD3-9DE1-EEE4AAB5967D

Q36590934-3EA53B9B-843C-4923-ACB4-38E1E8358505

Q36590934-444DF1F2-D911-4E20-9388-42C81297F978

Q36590934-4783BBFA-0632-4F45-A1AC-FBA05951996D

P304

Q36590934-E5457A09-F680-44E4-9803-F6A716CB0601

P31

Q36590934-3C9F2E12-3114-4CC4-90D2-D67DAB8BD96B

P356

Q36590934-E09F271E-5F31-4C83-9E4C-8FA9388DCAF8

P478

Q36590934-E0D2F2A4-C7B3-4AD0-A17F-1DEA62939A85

P577

Q36590934-D6816E72-048C-4F43-B8B6-14B0C9579234

P5875

Q36590934-B74B92FE-76CA-44D5-BC01-825FE9879251

P698

Q36590934-64AC8185-407B-4AC7-8857-62B2E5F65579

P932

Q36590934-3FF3D3C1-A5AF-422A-9966-AD81FAFF31D1

P356

P1433

Journal of Inherited Metabolic Disorders Reports

P1476

Effects of switching from agal ...... ts with anderson-fabry disease

@en

P2093

A Pisani

http://www.w3.org/2001/XMLSchema#string

B Visciano

http://www.w3.org/2001/XMLSchema#string

E Riccio

http://www.w3.org/2001/XMLSchema#string

G Messalli

http://www.w3.org/2001/XMLSchema#string

I Capuano

http://www.w3.org/2001/XMLSchema#string

L Spinelli

http://www.w3.org/2001/XMLSchema#string

M Imbriaco

http://www.w3.org/2001/XMLSchema#string

M Sabbatini

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

Natural history and treatment of renal involvement in Fabry disease.

Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.

The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.

The heart in Anderson-Fabry disease and other lysosomal storage disorders.

P304

41-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/8904_2012_177

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235691113

http://www.w3.org/2001/XMLSchema#string

P698

23430546

http://www.w3.org/2001/XMLSchema#string

P932

3565648

http://www.w3.org/2001/XMLSchema#string